Newly Diagnosed Anemia Increases Risk of Parkinson's disease: A Population-Based Cohort Study

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Hong, Chien Tai ^a,b   Huang, Yao Hsien ^a,b   Liu, Hung Yi ^c   Chiou, Hung Yi ^c   Chan, Lung ^a,b   Chien, Li Nien ^c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; COHORT ANALYSIS; COMPLICATION; FACTUAL DATABASE; FEMALE; HUMAN; IRON DEFICIENCY ANEMIA; MALE; METHODOLOGY; MIDDLE AGED; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODEL; PUBLIC HEALTH; RISK FACTOR; TAIWAN;

AGED; ANEMIA, IRON-DEFICIENCY; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODELS; RESEARCH DESIGN; RISK FACTORS; TAIWAN;

EID: 84978802739     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep29651     Document Type: Article

References (43)

1. de Lau, L. M. L. & Breteler, M. M. B. Epidemiology of Parkinson's's disease. The Lancet Neurology 5, 525, doi: 10.1016/S1474-4422(06)70471-9 (2006).
2. Schapira, A. H., Olanow, C. W., Greenamyre, J. T. & Bezard, E. Slowing of neurodegeneration in Parkinson's's disease and Huntington's disease: future therapeutic perspectives. Lancet 384, 545, doi: 10.1016/s0140-6736(14)61010-2 (2014).
3. Kalia, L. V., Kalia, S. K. & Lang, A. E. Disease-modifying strategies for Parkinson's's disease. Mov Disord 30, 1442, doi: 10.1002/mds.26354 (2015).
4. Olanow, C. W., Kieburtz, K. & Schapira, A. H. Why have we failed to achieve neuroprotection in Parkinson's's disease? Ann Neurol 64 Suppl 2, S101, doi: 10.1002/ana.21461 (2008).
5. Schapira, A. H. Progress in neuroprotection in Parkinson's's disease. Eur J Neurol 15 Suppl 1, 5, doi: 10.1111/j.1468-1331.2008.02055.x (2008).
6. Braak, H., Sastre, M., Bohl, J. R., de Vos, R. A. & Del Tredici, K. Parkinson's's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre-and postganglionic neurons. Acta Neuropathol 113, 421, doi: 10.1007/s00401-007-0193-x (2007).
7. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's's disease. Neurobiol Aging 24, 197 (2003).
8. Goldman, J. G. & Postuma, R. Premotor and nonmotor features of Parkinson's's disease. Curr Opin Neurol 27, 434, doi: 10.1097/wco.0000000000000112 (2014).
9. Pont-Sunyer, C. et al. The onset of nonmotor symptoms in Parkinson's's disease (the ONSET PD study). Mov Disord 30, 229, doi: 10.1002/mds.26077 (2015).
10. Adler, C. H. Premotor symptoms and early diagnosis of Parkinson's's disease. Int J Neurosci 121 Suppl 2, 3, doi: 10.3109/00207454.2011.620192 (2011).
11. Noyce, A. J., Lees, A. J. & Schrag, A.-E. The prediagnostic phase of Parkinson's's disease. Journal of Neurology, Neurosurgery & Psychiatry, doi: 10.1136/jnnp-2015-311890 (2016).
12. Pretorius, E. et al. Eryptosis as a marker of Parkinson's's disease. Aging (Albany NY) 6, 788 (2014).
13. Savica, R. et al. Anemia or low hemoglobin levels preceding Parkinson's disease: A case-control study. Neurology 73, 1381, doi: 10.1212/WNL.0b013e3181bd80c1 (2009).
14. Johannsen, P., Velander, G., Mai, J., Thorling, E. B. & Dupont, E. Glutathione peroxidase in early and advanced Parkinson's's disease. J Neurol Neurosurg Psychiatry 54, 679 (1991).
15. Urakami, K. et al. Decreased superoxide dismutase activity in erythrocyte in Parkinson's's disease. Jpn J Psychiatry Neurol 46, 933, (1992).
16. Kilinc, A., Yalcin, A. S., Yalcin, D., Taga, Y. & Emerk, K. Increased erythrocyte susceptibility to lipid peroxidation in human Parkinson's's disease. Neurosci Lett. 87, 307 (1988).
17. Lang, F., Abed, M., Lang, E. & Foller, M. Oxidative stress and suicidal erythrocyte death. Antioxid Redox Signal 21, 138, doi: 10.1089/ars.2013.5747 (2014).
18. Barbour, R. et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis. 5, 55, doi: 10.1159/000112832 (2008).
19. Wang, X., Yu, S., Li, F. & Feng, T. Detection of alpha-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's's disease. Neurosci Lett. 599, 115, doi: 10.1016/j.neulet.2015.05.030 (2015).
20. Martin, W. R., Wieler, M. & Gee, M. Midbrain iron content in early Parkinson's disease: a potential biomarker of disease status. Neurology 70, 1411, doi: 10.1212/01.wnl.0000286384.31050.b5 (2008).
21. Dexter, D. T. et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's's disease. J Neurochem 52, 1830 (1989).
22. Sofic, E. et al. Increased iron (III) and total iron content in post mortem substantia nigra of Parkinson'sian brain. J Neural Transm 74, 199 (1988).
23. Pichler, I. et al. Serum iron levels and the risk of Parkinson's disease: a Mendelian randomization study. PLoS Med. 10, e1001462, doi: 10.1371/journal.pmed.1001462 (2013).
24. Miyake, Y. et al. Dietary intake of metals and risk of Parkinson's's disease: a case-control study in Japan. J Neurol Sci. 306, 98, doi: 10.1016/j.jns.2011.03.035 (2011).
25. Cabantchik, Z. I., Munnich, A., Youdim, M. B. & Devos, D. Regional siderosis: a new challenge for iron chelation therapy. Frontiers in Pharmacology 4, 167, doi: 10.3389/fphar.2013.00167 (2013).
26. Kaneko, J. J. In Clinical Biochemistry of Domestic Animals (Third Edition) 649 (Academic Press, 1980).
27. Roberts, K. M. & Fitzpatrick, P. F. Mechanisms of tryptophan and tyrosine hydroxylase. IUBMB Life 65, 350, doi: 10.1002/iub.1144 (2013).
28. Nelson, C., Erikson, K., Piñero, D. J. & Beard, J. L. In Vivo Dopamine Metabolism Is Altered in Iron-Deficient Anemic Rats. The Journal of Nutrition 127, 2282 (1997).
29. Herrup, K. & Yang, Y. Cell cycle regulation in the postmitotic neuron: oxymoron or new biology? Nat Rev Neurosci 8, 368 (2007).
30. Savica, R., Rocca, W. A. & Ahlskog, J. WHen does Parkinson's disease start? Archives of Neurology 67, 798, doi: 10.1001/archneurol.2010.135 (2010).
31. Lee, Y. C. et al. Discontinuation of statin therapy associates with Parkinson's disease: a population-based study. Neurology 81, 410, doi: 10.1212/WNL.0b013e31829d873c (2013).
32. Kieburtz, K. & Wunderle, K. B. Parkinson's's disease: evidence for environmental risk factors. Mov Disord 28, 8, doi: 10.1002/mds.25150 (2013).
33. Gardner, R. C. et al. Traumatic brain injury in later life increases risk for Parkinson's disease. Ann Neurol 77, 987, doi: 10.1002/ana.24396 (2015).
34. Rosenbaum, P. R. & Rubin, D. B. Constructing a Control Group Using Multivariate Matched Sampling Methods That Incorporate the Propensity Score. The American Statistician 39, 33, doi: 10.2307/2683903 (1985).
35. Rosenbaum, P. R. & Rubin, D. B. The central role of the propensity score in observational studies for causal effects. Biometrika 70, 41, doi: 10.1093/biomet/70.1.41 (1983).
36. Faries, D. E. SAS Institute & Books24x7 Inc. (SAS Institute, Cary, N.C., 2010).
37. Austin, P. C. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med. 27, 2037, doi: 10.1002/sim.3150 (2008).
38. Austin, P. C., Grootendorst, P. & Anderson, G. M. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 26, 734, doi: 10.1002/sim.2580 (2007).
39. Guo, S. & Fraser, M. W. Propensity score analysis: statistical methods and applications. (Sage Publications, 2010).
40. Rees, K. et al. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's's disease: evidence from observational studies. Cochrane Database Syst Rev. Cd008454, doi: 10.1002/14651858.CD008454.pub2 (2011).
41. Zhou, B., Latouche, A., Rocha, V. & Fine, J. Competing risks regression for stratified data. Biometrics 67, 661, doi: 10.1111/j.1541-0420.2010.01493.x (2011).
42. Fine, J. P. & Gray, R. J. A Proportional Hazards Model for the Subdistribution of a Competing Risk. Journal of the American Statistical Association 94, 496, doi: 10.2307/2670170 (1999).
43. Pearce, N. Analysis of matched case-control studies. BMJ. 352 (2016).